Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) EBITDA (2021 - 2025)

Lucid Diagnostics' EBITDA history spans 5 years, with the latest figure at $23.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 289.47% year-over-year to $23.4 million; the TTM value through Dec 2025 reached -$12.2 million, up 73.55%, while the annual FY2025 figure was -$12.2 million, 73.55% up from the prior year.
  • EBITDA reached $23.4 million in Q4 2025 per LUCD's latest filing, up from -$11.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $23.4 million in Q4 2025 to a low of -$15.0 million in Q4 2022.
  • Average EBITDA over 5 years is -$9.5 million, with a median of -$11.5 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 235.92% in 2022, then skyrocketed 289.47% in 2025.
  • A 5-year view of EBITDA shows it stood at -$11.2 million in 2021, then tumbled by 33.22% to -$15.0 million in 2022, then rose by 23.52% to -$11.5 million in 2023, then dropped by 8.05% to -$12.4 million in 2024, then surged by 289.47% to $23.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's EBITDA are $23.4 million (Q4 2025), -$11.8 million (Q3 2025), and -$11.4 million (Q2 2025).